| 000 | 01730nam a2200241Ia 4500 | ||
|---|---|---|---|
| 003 | NULRC | ||
| 005 | 20250520102739.0 | ||
| 008 | 250520s9999 xx 000 0 und d | ||
| 020 | _a9780470487532 | ||
| 040 | _cNULRC | ||
| 050 | _aHD 9666.5 .E45 2012 | ||
| 100 |
_aEllery, Tony _eauthor |
||
| 245 | 0 |
_aPharmaceutical lifecycle management : _bmaking the most of each and every brand / _cTony Ellery and Neal Hansen |
|
| 260 |
_aHoboken, New Jersey : _bJohn Wiley & Son, Inc., _cc2012 |
||
| 300 |
_axxii, 389 pages : _billustrations ; _c24 cm. |
||
| 365 | _bUSD63.53 | ||
| 504 | _aIncludes bibliographical references and index. | ||
| 505 | _apt. A. Lifecycle management business environment -- pt. B. Lifecycle management regulatory and legal environment -- pt. C. Patents and exclusivities -- pt. D. Developmental LCM -- pt. E. Commercial LCM -- pt. F. Biologics and biosimilars -- pt. G. The integrated brand LCM strategy and its implementation -- pt. H. Integrating LCM with portfolio management. | ||
| 520 | _aA comprehensive guide to optimizing the lifecycle management of pharmaceutical brandsThe mounting challenges posed by cost containment policies and the prevalence of generic alternatives make optimizing the lifecycle management (LCM) of brand drugs essential for pharmaceutical companies looking to maximize the value of their products. Demonstrating how different measures can be combined to create winning strategies, Pharmaceutical Lifecycle Management: Making the Most of Each and Every Brand explores this increasingly important field to help readers understand what they can--and must--do to get. | ||
| 650 | _aDRUG APPROVAL -- ECONOMIC ASPECTS | ||
| 700 |
_aHansen, Neal _eco-author |
||
| 942 |
_2lcc _cBK |
||
| 999 |
_c14372 _d14372 |
||